Trial · NCT02950311
Xylitol for Otitis Media
NCT02950311, Phase 2, Phase 3, Withdrawn, Duke University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Xylitol for Otitis Media. Trials, record NCT02950311. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02950311
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Xylitol for Otitis Media
- NCT number
- NCT02950311
- Status
- Withdrawn
- Phases
- Phase 2, Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- Duke University
- Conditions
- Otitis Media With Effusion
- Interventions
- Intranasal xylitol spray, Intranasal saline spray
- First posted
- 2016-11-01
- Last updated
- 2017-12-22
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to middle ear effusion resolution | 24 weeks | |
| Secondary | To evaluate the effect of intranasal xylitol on resolution of the conductive hearing loss associated with middle ear effusion | 24 weeks | Results from both audiometry and tympanometry testing are combined to have a comprehensive assessment of conductive hearing loss. |
| Secondary | Effect of intranasal xylitol on frequency of episodes of acute otitis media and sinonasal symptoms | 24 weeks | |
| Secondary | Tolerability and side effects of intranasal xylitol administration in children | 24 weeks | Will be evaluated descriptively and include all subjects exposed to at least one dose of study drug |
| Secondary | Tympanostomy tube (TT) placement need | 24 weeks | The number of subjects that need TT placement in each arm will be assessed. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02950311
GET https://conductscience.org/api/trials/v1/NCT02950311/registered